The change of administrations in Washington, DC may undermine the future of a proposal to revise Medicare Part B drug compensation, a plan that has been widely criticized in the oncological community because of the potential reduction in profit margins it entails.

This week, the Community Oncology Alliance (COA) was cheering the passage of an important date for action that has not yet occurred: the release of the “final rule” for the Part B Drug Payment Model. According to the original plan, the proposed drug model could not be put into effect until 60 days after the release of the final rule. Had the rule been released last week, the Obama administration would still be in office in time to implement the program. Now, in 60 days’ time, the Trump administration will be in charge, and there is little support among Republicans for the payment model.

Continue Reading on OncLive